Condition: Advanced Urothelial Carcinoma · Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd.
To evaluate the efficacy and safety of SHR-A2102 for injection versus Investigator-selected Therapy in patients with Locally advanced or Metastatic Urothelial Carcinoma who have been previously treated with platinum-based chemotherapy and PD-(L)1 inhibitors.
This description comes directly from the study's public registry record.
Chi Zhang, M.M · +86-18456513908 · chi.zhang@hengrui.com
Zhaoxiang Wang, M.M · +86-19181783204 · zhaoxiang.wang.zw170@hengrui.com
Always discuss trial participation with your own doctor first.
| Beijing Cancer Hospital | Beijing, Beijing Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06738251